Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration

Sunnyvale, July 16, 2018 (GLOBE NEWSWIRE) -- July 16, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH).  The instrumentation reads and reports test results for the company’s allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson’s Disease (PD).

Arrayit recently scored 100% on immunoglobulin E (IgE) proficiency testing with the College of American Pathologists, announced a nationwide sales network of 1,700 professional sales representatives to sell and distribute the company’s finger stick tests, and completed pilot testing with one the nation’s largest chains of retail stores.  Arrayit microarray tests conveniently use a few drops of blood collected on a blood card to assist doctors in identifying and treating allergy, asthma, dietary intolerance and pipeline indications for ovarian cancer and PD.  The company recently met with top officials at the FDA to discuss FDA approval of a major product line.  The FDA ensures the safety of food, drugs and medical devices by regulating consumer products exceeding $1,000,000,000,000 ($1 trillion) in annual revenues.

Arrayit CEO Rene Schena states, “The sale of clinical instrumentation to the FDA advances our personalized medicine initiatives by strengthening ties with the nation’s preeminent regulatory agency.  Our transformative healthcare products and services benefit from transparency in the hands of top FDA scientists.”

About Arrayit

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit for more information.

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.

CONTACT

Public Relations

Arrayit Corporation

Tel: 408-744-1331

Email:

Web: